Trial record 2 of 2 for:    Seciera

Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca (Emerald)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02688556
Recruitment Status : Completed
First Posted : February 23, 2016
Last Update Posted : February 17, 2017
Information provided by (Responsible Party):
Ocular Technologies SARL

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : November 2016
  Actual Study Completion Date : December 2016